Platelet aggregation-IN-3

Platelet aggregation-IN-3 (Compound 5) is a ligand for H2 histamine receptors, α2 (A, C) -adrenergic receptors (α2-AR), and 5-HT2 (B, C) serotonin receptors. Platelet aggregation-IN-3 can inhibit platelet aggregation induced by ADP and collagen and can also modulate tumour cell-induced platelet aggregation (TCIPA) . Platelet aggregation-IN-3 is promising for research of antiplatelet therapy in cardiovascular diseases and the prevention of cancer-related thrombosis and tumour metastasis[1].

Product Specifications

CAS Number

[1029802-21-8]

UNSPSC

12352005

Target

5-HT Receptor; Adrenergic Receptor; Histamine Receptor

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Smiles

C1(NC2=CC=C3C(CCCC3)=C2)=NCCN1.Cl

Molecular Formula

C13H18ClN3

Molecular Weight

251.76

References & Citations

[1]Hante NK, et al. Effect of mono-guanidine-like derivatives on platelet aggregation and tumour cell induced platelet aggregation. RSC Med Chem. 2025 Jan 31;16 (4) :1695-1704.